Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Onchocerciasis Treatment Market: By Drug Class Type, By Distribution Channel, and Region
Onchocerciasis Treatment Market: By Drug Class Type, By Distribution Channel, and Region
Onchocerciasis (River Blindness) Treatment Market size was valued at US$ 2.33 billion in 2023 and is poised to grow at a CAGR of 6.3% from 2024-2030. Onchocerciasis, often known as river blindness, is a parasitic worm infection caused by the Onchocerca volvulus. Bumps under the skin, intense itching, and blindness are all signs of onchocerciasis. After trachoma, onchocerciasis is the second most prevalent cause of infection-related blindness. The disease is spread by infected blackflies biting humans. These black flies breed near settlements and agricultural land, where they breed along streams and fast-flowing rivers.
Adult onchocerciasis worms produce microfinance (embryonic larvae) in the human body, which can travel to the eyes, skin, and other organs. The majority of people affected with this disease live in African countries. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Study Period
2024-2030Base Year
2023CAGR
6.3%Largest Market
North-AmericaFastest Growing Market
Europe
In recent years, the onchocerciasis treatment market has been influenced by soaring market capitalization of smaller players, increasing number of strategic partnerships to scoop out the best of emerging medications or drugs, increased R&D spending by big pharma and emerging players, expanded indications for approved drugs, and rising competition between companies producing drugs for the same indications have all influenced demand. Following 15-17 years of therapy, a recent evaluation in Mali and Senegal has confirmed the primary confirmation of disposal. Following this discovery, the African Program for Onchocerciasis Control (APOC) has launched a thorough examination of the long-term effects of ivermectin treatment projects and the viability of completion in APOC-supported countries.
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 2.33 billion |
|
Market CAGR |
6.3% |
|
By Drug Class |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The global onchocerciasis river blindness treatment market size was valued at US$ 2.33 billion in 2023 and is projected to grow at a CAGR of 6.3% from 2024 to 2030.
The onchocerciasis (river blindness) treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Increased Incidence of River Blindness
| 1.Executive Summary |
| 2.Global Onchocerciasis River Blindness Treatment Market Introduction |
| 2.1.Global Onchocerciasis River Blindness Treatment Market - Taxonomy |
| 2.2.Global Onchocerciasis River Blindness Treatment Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Onchocerciasis River Blindness Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Onchocerciasis River Blindness Treatment Market Analysis, 2019-2023 and Forecast 2024-2030 |
| 4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Onchocerciasis River Blindness Treatment Market By Drug Class, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 5.1. Anthelmintic drugs |
| 5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 6.Global Onchocerciasis River Blindness Treatment Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacies |
| 6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacies |
| 6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Onchocerciasis River Blindness Treatment Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Onchocerciasis River Blindness Treatment Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 8.1. Drug Class Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Anthelmintic drugs |
| 8.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacies |
| 8.2.2.Retail Pharmacies |
| 8.2.3.Online Pharmacies |
| 8.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Onchocerciasis River Blindness Treatment Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 9.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Anthelmintic drugs |
| 9.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacies |
| 9.2.2.Retail Pharmacies |
| 9.2.3.Online Pharmacies |
| 9.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 9.3.7. |
| 10.Asia Pacific (APAC) Onchocerciasis River Blindness Treatment Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Anthelmintic drugs |
| 10.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacies |
| 10.2.2.Retail Pharmacies |
| 10.2.3.Online Pharmacies |
| 10.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Onchocerciasis River Blindness Treatment Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Anthelmintic drugs |
| 11.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacies |
| 11.2.2.Retail Pharmacies |
| 11.2.3.Online Pharmacies |
| 11.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Onchocerciasis River Blindness Treatment Market ,2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Anthelmintic drugs |
| 12.2. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacies |
| 12.2.2.Retail Pharmacies |
| 12.2.3.Online Pharmacies |
| 12.3. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Merck & Co., Inc. (U.S) |
| 13.2.2.Mayne Pharma Group (Australia) |
| 13.2.3.Delta Pharma Ltd., (India) |
| 13.2.4.Par Pharmaceutical Companies, Inc.(U.S) |
| 13.2.5.Taj Pharmaceuticals Limited (India) |
| 13.2.6.Sigma-Aldrich Co. LLC (U.S) |
| 13.2.7. |
| 13.2.8. |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.